Multi-View Deep Learning for Automated Quantification of Mitral Stenosis
Abstract Body (Do not enter title and authors here): Background: Accurate assessment of mitral stenosis (MS) severity is critical to guide timely clinical management. Current evaluation relies on expert interpretation of B-mode and Doppler echocardiography, requiring integration of multiple views and skilled Doppler imaging. This study aimed to develop and validate a deep learning model for automated MS severity assessment using multi-view B-mode and color Doppler echocardiographic videos. Methods: We developed a two-stage framework for automated MS assessment. First, four video-based convolutional neural networks were trained to classify MS severity from distinct echocardiographic views: B-mode [parasternal long-axis (PLAX), apical three-chamber and five-chamber (AP)] and color Doppler [PLAX-color, and AP-color]. Next, outputs from the four models were integrated using a machine learning ensemble (HistGradientBoostingClassifier) to produce a study-level MS severity classification. Performance was assessed using area under the receiver operating characteristic curve (AUC) on held-out test set from Kaiser Permanente (KP) and Stanford Health Care (SHC). Results: The models were trained on 66,714 videos from 3,921 studies at KP, and evaluated on internal held-out test data (KP; 7,344 videos, 438 studies) and external test data (SHC; 29,181 videos, 1,988 studies). The multi-view ensemble model demonstrated strong performance, achieving a macro-AUC of 0.853 (95% CI: 0.828–0.877; Figure 1) on the KP test dataset. Generalizability was confirmed on the external SHC cohort with an AUC of 0.974 (95% CI: 0.968–0.981; Figure 2). Conclusion: This study confirmed the ability for multi-view deep learning models to assess MS severity. The model demonstrated accurate, generalizable performance and highlights the potential of AI-powered decision support tools in echocardiographic evaluation of MS.
Ieki, Hirotaka
( Stanford University
, Stanford
, California
, United States
)
Vukadinovic, Milos
( Kaiser Permanente
, Pleasanton
, California
, United States
)
Sahashi, Yuki
( Cedars-Sinai Medical Center
, Beverly Hills
, California
, United States
)
He, Bryan
( Stanford
, Stanford
, California
, United States
)
Cheng, Paul
( Stanford University
, Stanford
, California
, United States
)
Ouyang, David
( Kaiser Permanente
, Pleasanton
, California
, United States
)
Author Disclosures:
Hirotaka IEKI:DO NOT have relevant financial relationships
| Milos Vukadinovic:No Answer
| Yuki Sahashi:DO have relevant financial relationships
;
Consultant:m3:Active (exists now)
| Bryan He:No Answer
| Paul Cheng:No Answer
| David Ouyang:DO have relevant financial relationships
;
Consultant:InVision:Active (exists now)
; Consultant:Pfizer:Past (completed)
; Consultant:Ultromics:Past (completed)
; Consultant:EchoIQ:Past (completed)
; Consultant:AstraZeneca:Active (exists now)